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The objective of this research was to develop and validate an alternative analytical method for quantitative determination of levofloxacin 
in tablets and injection preparations. The calibration curves were linear over a concentration range from 3.0 to 8.0 μg mL-1. The relative 
standard deviation was below 1.0% for both formulations and average recovery was 101.42 ± 0.45% and 100.34 ± 0.85% for tablets 
and injection formulations, respectively. The limit of detection and limit of quantitation were 0.08 and 0.25 μg mL-1, respectively. It was 
concluded that the developed method is suitable for the quality control of levofloxacin in pharmaceuticals formulations.
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INTRODUCTION
Quinolones are antimicrobials, structurally related to nalidixic 
acid, which were made available for clinical use in urinary infections, 
since 1960s.1,2 They are used in human and veterinary medicine, 
especially in animal breeding area.1,2 Considerable amounts of qui-
nolones are widely used under field conditions (in poultry, swine, and 
cattle production), both in the treatment of infections and as growth 
promoters.1 The bactericidal activity of levofloxacin is mediated by 
the inhibition of DNA gyrase (topoisomerase II) and topoisomerase 
IV, essential enzymes involved in bacterial DNA replication, trans-
cription, repair and recombination.3
Levofloxacin (Figure 1, CAS number 100986-85-4) is pure (–)-(S)-
enantiomer of the racemic drug substance ofloxacin, which was introdu-
ced in 1997.  A third-generation fluoroquinolone with a wide spectrum 
of action against gram-positive and gram-negative bacteria, anaerobic 
microorganisms, and atypical pathogens.4 Levofloxacin prepared as 
hemihydrate, whose molecular mass is 369.93 g mol-1, is presented as 
white to light yellow needlelike crystals, that melt at approximately 
226 ºC. Its solubility is nearly constant from pH 0.6 to 5.8 (100.0 mg 
mL-1). Above pH 5.8, solubility increases sharply, reaching a maximum 
of 272 mg mL-1 at pH 6.7, beyond which it decreases to a minimum 
of 50.0 mg mL-1.5 Levofloxacin is the quinolone of choice for airway 
infections, being active against several types of pathogens.1,2,4,6
Various analytical methods have been reported in scientific literature 
for the analysis of levofloxacin in pharmaceutical formulation and/or 
biological fluids including high-performance liquid-chromatography with 
UV detection (HPLC-UV),7 vibrational spectroscopy,8 spectrofluorimetry 
(SF),9 colorimetric spectrophotometry (CS),9,10 spectrophotometry by 
ion-pair complex (CIPS),10-12 and UV spectrophotometry (UVS).13 
Most spectrophotometric methods in the literature for analysis of 
levofloxacin is based on the formation of ion-complexes,10-12 which use 
dye as Eriochrome black,12 bromophenol blue, bromocresol green,10,12 
eosin, merbromin11 and chromogenic reagent such as Folin-Ciocalteau.12 
The addition of these substances usually increases the cost of analysis and 
sample preparation is time consuming. Besides cost, toxicity of reagents 
and solvents used in the analysis should also be considered. Exposure 
to merbromin even at low concentrations and short exposure time can 
cause poisoning. The complexes formed normally need extraction with 
organic solvents, for example, chloroform,10,12 which in addition to further 
increase the cost of analysis and require safe handling and proper disposal.
Recently an UVS method was proposed with acetonitrile as 
solvent for the quantitative determination of levofloxacin in tablets 
and solution.13 This solvent is more toxic and more expensive than 
methanol. Therefore, the proposed method is less toxic to the analyst 
when compared with the solvent acetonitrile and is more economical.
In addition, there are no official methods for determination of 
this active substance.14,15
Thus, the aim of this study was to develop and validate a fast, 
simple and cost-effective UV-spectrophotometric alternative method 
for analysis of two commercial formulations of levofloxacin.
EXPERIMENTAL
Material
The levofloxacin reference substance (assigned purity 100.0%) 
and levofloxacin pharmaceutical dosage forms were kindly donated 
by local pharmaceutical industries and were used as reference stan-
Figure 1. Chemical structure of Levofloxacin
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dards without further purification. The commercial levofloxacin (free 
base) dosage forms used were tablets containing 250 mg of the active 
substance (declared content), and injection vial of 100 mL, with 5 mg 
mL-1 (declared concentration). The levofloxacin reference substance, 
as well as the tablets and injection vial, were kept protected from 
light throughout the whole procedure. Methanol was HPLC grade.
Instrumentation and conditions
A HP 8453 UV-Visible Spectrophotometer with data processing 
system was used. UV spectra absorbance of reference and sample 
solutions were recorded in 10 mm quartz cells at 298 nm. The solu-
tions were prepared in methanol.
Methods
Preparation of standard solutions
The levofloxacin reference standard solution (200.0 μg mL-1) was 
prepared by accurately weighing 20.0 mg of levofloxacin reference 
in a 100.0 mL volumetric flask. The volume was completed with 
methanol. This flask was sonicated for 25 min. The above solution 
was diluted in a 100 mL volumetric flask with methnol to obtain a 
final solution containing 10.0 μg mL-1 of levofloxacin. 
Determination of maximum absorption λ
max. 
From the standard solution (200.0 μg mL) approximately 3.0 mL 
was taken and scanned from 200 to 400 nm with HP 8453 UV-Visible 
spectrophotometer. The methanol was used as blank. Levofloxacin 
presented maximum absorption at 298 nm.
Calibration curve
The calibration curve was constructed by analyzing 6 different 
concentrations of standard solution, prepared on the same day. The 
range of solutions varied from 3.0 to 8.0 μg mL-1. All determinations 
were conducted in triplicate.
Sample preparation
Levofloxacin tablets
To analyze the concentration of levofloxacin tablets, 20 tablets of 
each sample were individually weighed and triturated to obtain homo-
geneous mixture. An amount of powder equivalent to 100.0 mg of free 
base was transferred to 100.0 mL volumetric flask. The volume was 
completed with methanol. The resulting solution was sonicated during 
25 min to facilitate proper solubilization. Aliquots of this solution were 
accordingly diluted with methanol, in order to obtain a solution with 
final concentration of 5.0 μg mL-1. All sample and standard solution were 
filtered through hydrophilic membrane of 0.45 μm pore size - Millipore® 
Millex-HV filter units. All determinations were conducted in triplicate.
Levofloxacin injection
To analyze the concentration of levofloxacin injection, 5.0 mL of 
injection formulation (theoretical content 5 mg mL-1) was used for sam-
ple solution preparation. The procedure adopted for the preparation of 
injectable sample was similar to that described for tablets. Appropriate 
dilutions were made with methanol to final solution containing 5.0 μg 
mL-1 of drug as free base. All determinations were conducted in triplicate.
Method validation
Linearity
The linearity was determined by plotting concentration against 
corresponding absorbance. The calibration curve was defined in the 
concentration interval in which the intensity of the spectrophotome-
ter response was linearly proportional to the concentration of the 
analyzed substance:
A = a.C + b (1)
where A is the absorbance; C, concentration of sample; a, slope of 
the curve; and, b, y intercept of the curve.
 The linearity was evaluated by linear regression analysis, which 
was calculated by the least square regression method and the corre-
lation coefficient (r) indicated the linearity of the method.
Precision
The intra-day precision was determined by analyzing the samples 
of levofloxacin at concentrations of 5.0 μg mL-1. Determinations 
were performed with ten replicates on the same day. The precision 
is expressed as relative standard deviation (RSD) amongst responses. 
In order to be considered precise, the RSD of the method should be 
less than 2.0%.
Accuracy
The accuracy of the method was evaluated through the recovery 
test. Recovery tests were performed by adding known amounts of 
standard solutions to samples followed by analyses using the proposed 
method. Aliquots of standard and samples solutions were transferred 
to 10 mL volumetric flasks and final volumes were completed with 
methanol. The percentage of recovery (R) was calculated as indicated 
by Association of Official Analytical Chemists International:16
R = [ ( CF – CU ) / CA ] x 100 (2)
where CF represents the concentration of analyte measure in fortified 
test sample; CU , the concentration of analyte measure in unfortified 
test sample; and, CA , the concentration of analyte added to fortified 
test sample.
Specificity
Specificity is the ability of the method to accurately measure 
a compound in the presence of other components such as impuri-
ties, degradation products and matrix components. The specificity 
of the proposed method was evaluated through the analysis of a 
placebo solution, which it was prepared with the excipients of the 
pharmaceutical formulation. Thus, the mixture of component inert 
was prepared in their usual concentration employed in tablets than 
the method was applied in order to check if any component of the 
formulation could generate a response or a read with absorption 
band similar to the drug.
Limit of detection and limit of quantitation
The limit of detection (LOD) and limit of quantitation (LOQ) 
were calculated according to International Conference on Harmo-
nization guidelines:17
LOD = 3.3 · SDb / a (3)
LOQ = 10.0 · SDb / a (4)
where SDb represents the standard deviation of y-intercept and a is 
the slope of calibration curve.
Statistical analysis
All statistical analysis was calculated using spreadsheet programs 
and SPSS Software.18
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RESULTS AND DISCUSSION
Levofloxacin was analyzed by proposed UV spectrophotometric 
method in tablets and injections. The calibration curve showed linea-
rity over a concentration range from 3.0 to 8.0 μg mL-1. The linearity 
can be defined by following equation A = 0.0981C + 0.0019 (Figure 
2), where A and C are levofloxacin absorbance and concentration, 
respectively. The correlation coefficients of the curve obtained with 
linear regression method were 0.9999.
The RSD amongst ten measurements for each sample found to be 
0.45 and 0.34% for tablets and injection forms, respectively (Table 
1). The percentages content were 98.32 ± 0.01% and 99.20 ± 0.01% 
for tablets and injection forms, respectively (Table 1). 
The recovery values obtained were 101.42 ± 0.45% and 100.34 ± 
0.85% for tablets and injections forms, respectively, by using Equa-
tion 2. These results confirm accuracy of the proposed method. The 
percentage of recovery results are presented in Table 2.
The assays were validated by means of the analysis of variance, 
as described in official literature. This developed method presented 
no parallelism deviation and no linearity deviation (P < 0.05). The 
precision and accuracy of the assay were demonstrated.
The excipients present in pharmaceutical dosage form (tablets) 
do not interfere in the analysis. The results prove specificity of the 
proposed methods for inequivocal identification of analyte in the 
presence of matrix compounds (excipients).
The LOD and LOQ were 0.08 and 0.25 μg mL-1, by using Equa-
tions 3 and 4, respectively.
While comparing proposed analytical method for determination 
of levofloxacin in pharmaceutical formulations with those reported 
in literature, it can be observed that:
Linearity range: reported HPLC-UV,7 CS,9 CIPS,10,11 and UVS,13 
methods presented significantly higher linearity range, 20.0, 25.0, 
29.65, and 10.00 μg mL-1, respectively;
Accuracy: all reported methods are equally accurate;
Precision: CIPS method using bromophenol blue or bromocresol 
green,10,12 presented RSD values near 0.06%. While SF,9 UVS,13 and 
HPLC-UV7 method had RSD values near 0.56, 0.65, and 0.56%, 
respectively;
LOD and LOQ: the reported LOD and LOQ values in the literature 
are high, that makes our method more sensitive.
It is important to observe that only two methods7,9 were fully 
validated and applied in the analysis of Levofloxacin in tablets and 
injection formulations.
CONCLUSION
In this study, the developed and validated UV-spectrophoto-
metric alternative method for the determination of levofloxacin 
in pharmaceutical formulations has the advantage of being fast, 
simple, cost-effective with high precision, and accuracy. These 
advantages encourage the application of this method in routine 
analysis of levofloxacin.
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